We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-7.21%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.1B
AUM Growth
-$504M
Cap. Flow
-$227M
Cap. Flow %
-10.82%
Top 10 Hldgs %
55.38%
Holding
76
New
4
Increased
13
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$39M
2
BSX icon
Boston Scientific
BSX
+$20.1M
3
BHVN icon
Biohaven
BHVN
+$10.8M
4
RGNX icon
Regenxbio
RGNX
+$9.92M
5
EVH icon
Evolent Health
EVH
+$7M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$68.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$42.4M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.4M
4
FOLD
Amicus Therapeutics
FOLD
+$33.8M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.1%
2 Industrials 3.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
1
DELISTED
Immunogen Inc
IMGN
$278M 13.22%
17,503,417
-227,000
-1% -$3.78M
KRYS icon
2
Krystal Biotech
KRYS
$10B
$232M 11.06%
2,003,367
-563,294
-22% -$68.7M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$206M 9.8%
16,944,621
-2,622,340
-13% -$33.8M
AKRO
4
DELISTED
Akero Therapeutics
AKRO
$89.5M 4.26%
1,769,684
-41,988
-2% -$1.96M
AUGX
5
DELISTED
Augmedix, Inc. Common Stock
AUGX
$80.5M 3.83%
15,630,327
– –
REPL icon
6
Replimune Group
REPL
$882M
$71.2M 3.39%
4,163,922
-256,611
-6% -$5.04M
LIVN icon
7
LivaNova
LIVN
$4.35B
$58.2M 2.77%
1,100,492
– –
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$56.9M 2.71%
4,475,384
-403,182
-8% -$5.56M
PLRX icon
9
Pliant Therapeutics
PLRX
$66.3M
$46.4M 2.21%
2,678,099
– –
CLDX icon
10
Celldex Therapeutics
CLDX
$2.78B
$45M 2.14%
1,635,938
-60,066
-4% -$1.88M
RGNX icon
11
Regenxbio
RGNX
$557M
$42.4M 2.02%
2,574,042
+547,466
+27% +$9.92M
IMVT icon
12
Immunovant
IMVT
$8.2B
$42.3M 2.01%
1,102,514
-818,638
-43% -$18.5M
RYZB
13
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$41.2M 1.96%
+1,857,706
New +$39M
BSX icon
14
Boston Scientific
BSX
$65.1B
$40.9M 1.94%
774,200
+383,022
+98% +$20.1M
CTLT
15
DELISTED
CATALENT, INC.
CTLT
$39.8M 1.89%
873,966
-288,200
-25% -$13.5M
PEN icon
16
Penumbra
PEN
$12.5B
$37.5M 1.78%
155,076
+16,106
+12% +$4.47M
ELV icon
17
Elevance Health
ELV
$82.9B
$37.2M 1.77%
85,378
+7,065
+9% +$3.2M
ZYME icon
18
Zymeworks
ZYME
$1.75B
$35.9M 1.71%
5,661,230
– –
BEAM icon
19
Beam Therapeutics
BEAM
$2.71B
$35.3M 1.68%
1,469,725
-15,474
-1% -$415K
SRRK icon
20
Scholar Rock
SRRK
$6.07B
$33.6M 1.6%
4,733,248
+329,408
+7% +$2.21M
VTYX
21
DELISTED
Ventyx Biosciences
VTYX
$32.3M 1.54%
929,900
-10,593
-1% -$366K
HUM icon
22
Humana
HUM
$47.8B
$29.1M 1.39%
59,851
+13,541
+29% +$6.36M
RPTX
23
DELISTED
Repare Therapeutics
RPTX
$29M 1.38%
2,404,695
-23,640
-1% -$244K
FATE icon
24
Fate Therapeutics
FATE
$325M
$27.8M 1.32%
13,124,427
– –
CABA icon
25
Cabaletta Bio
CABA
$448M
$27M 1.28%
1,774,252
+403,953
+29% +$5.52M
1
2 3 4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q3 2023 Portfolio in Review

As of Q3 2023, Redmile Group held 76 positions worth $2.1B, down 19% from $2.61B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $227M in Q3 2023, closing 8 positions and reducing 26 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $42.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in RayzeBio, Inc. Common Stock worth $41.2M.

  • Redmile Group's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,857,706 shares worth $41.2M.
  • Redmile Group added most to Boston Scientific in Q3 2023, an estimated $20.1M increase.
  • Redmile Group's biggest Q3 2023 reduction was Krystal Biotech, cutting an estimated $68.7M.
  • Redmile Group fully exited BioMarin Pharmaceuticals in Q3 2023, selling an estimated $42.4M.
  • Redmile Group's ten largest holdings make up 55% of its $2.1B portfolio in Q3 2023.
  • Redmile Group opened 4 new positions and closed 8 in Q3 2023.
  • Redmile Group's portfolio value fell 19% quarter-over-quarter to $2.1B.

Based on Redmile Group's 13F filing for Q3 2023, filed 14 Nov 2023.